Laboratorio Farmaceutico Erfo SpA

As of June 30, 2024, Laboratorio Farmaceutico Erfo SpA carries a market capitalization of 9.83M, placing it among publicly traded companies globally. Its enterprise value stands at 8.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Laboratorio Farmaceutico Erfo SpA's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2024, Laboratorio Farmaceutico Erfo SpA has 8.48M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Laboratorio Farmaceutico Erfo SpA maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Laboratorio Farmaceutico Erfo SpA's stock has declined approximately 38.76% over the past 52 weeks. The 50-day moving average sits at 1.10, while the 200-day moving average is 1.18.

As of June 30, 2024, Laboratorio Farmaceutico Erfo SpA holds 1.52M in cash and equivalents against 398,015.00 in total debt, resulting in a net debt position of -1.13M. Total book value stands at 7.52M, with working capital of 1.52M providing operational flexibility.